Lanthanum carbonate (Fosrenol) is safe and effective for the treatment of hemodialysis patients with hyperphosphatemia, according to two presentations on Nov. 2 at the American Society of Nephrology 35th annual meeting in Philadelphia, Pennsylvania.
Treatment with this noncalcium, nonaluminum phosphate binder in a chewable tablet formulation reportedly reduced deaths among kidney hemodialysis patients by 50%. “About 50% to 60% of patients on chronic hemodialysis do not have adequate phosphorus control; they have high phosphorus levels,” presenter William Finn, from the University of North Carolina at Chapel Hill, says in a news release. “I think this drug, Fosrenol, or drugs like it will become the preferred phosphate binders.”
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!